SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Amendment No. 3)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
GLOBAL MED TECHNOLOGIES, INC.
(Name of Subject Company (Issuer))
Atlas Acquisition Corp.
(Names of Filing Persons (Offerors))
Common Stock, $0.01 par value per share, and
Series A Convertible Preferred Stock, $0.01 par value per share
(Title of Class of Securities)
(CUSIP Number of Class of Securities)
Brian P. Concannon
President and Chief Executive Officer
400 Wood Road
Braintree, Massachusetts 02184
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications on Behalf of Filing Persons)
|James S. OShaughnessy, Esq.
400 Wood Road
Braintree, Massachusetts 02184
||Lisa R. Haddad, Esq.
Goodwin Procter LLP
53 State Street
Boston, Massachusetts 02109
CALCULATION OF FILING FEE
||Amount of Filing Fee**
||Estimated solely for purposes of calculating amount of filing fee in
accordance with Rule 0-11 under the Securities Exchange Act of 1934,
as amended (the Exchange Act). The transaction value is based upon
the offer to purchase up to 54,653,157 shares of Common Stock of
Global Med Technologies, Inc. at a purchase price of $1.22 cash per
share and 3,960 shares of Series A Convertible Preferred Stock at a
purchase price of $1,694.44 cash per share. Such number of shares of
Common Stock represents the total of 38,160,594 issued and outstanding
shares of Common Stock, outstanding options with respect to 6,420,271
shares of Common Stock, and outstanding warrants with respect to
10,072,292 shares of Common Stock, in each case as of February 18,
2010. Such number of shares of Series A Convertible Preferred Stock
represents all issued and outstanding shares of Series A Convertible
Preferred Stock as of February 18, 2010.
||The amount of the filing fee, calculated in accordance with Rule 0-11
of the Exchange Act, equals 0.00007130 of the transaction valuation.
||Check the box if any part of the fee is offset as provided by Rule
0-11(a)(2) and identify the filing with which the offsetting fee
was previously paid. Identify the previous filing registration
statement number, or the Form or Schedule and the date of its
Amount Previously Paid: $5,233
||Filing Party: Haemonetics Corporation and Atlas Acquisition Corp.
Form or Registration No.: Schedule TO
||Date Filed: February 19, 2010
||Check the box if the filing relates solely to preliminary
communications made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which the statement relates:
þ third-party tender offer subject to Rule 14d-1.
o issuer tender offer subject to Rule 13e-4.
o going-private transaction subject to Rule 13e-3.
o amendment to Schedule 13D under Rule 13d-2.
Check the following box if the filing is a final amendment reporting the results of the tender
TABLE OF CONTENTS
This Amendment No. 3 (this Amendment) amends and supplements the Tender Offer Statement on
Schedule TO filed with the Securities and Exchange Commission (the SEC) on February 19, 2010, as
amended by that certain Amendment No. 1 to the Schedule TO filed with the SEC on February 25, 2010
and that certain Amendment No. 2 to the Schedule TO filed with the SEC on March 9, 2010 (as so
amended, the Schedule TO). The Schedule TO relates to the offer by Atlas Acquisition Corp., a
Colorado corporation (Acquisition Corp.) and a direct wholly-owned subsidiary of Haemonetics
Corporation, a Massachusetts corporation (Haemonetics), to purchase all of the outstanding shares
of common stock, $0.01 par value per share (the Common Shares), of Global Med Technologies, Inc.,
a Colorado corporation (Global Med), at a purchase price of $1.22 per Common Share, net to the
seller in cash, without interest thereon, less any applicable withholding taxes, and to purchase
all of the outstanding shares of Global Meds Series A Convertible Preferred Stock, $0.01 par value
per share (the Preferred Shares, and together with the Common Shares, the Shares), at a
purchase price of $1,694.44 per Preferred Share, net to the seller in cash, without interest
thereon, less any applicable withholding taxes, upon the terms and subject to the conditions set
forth in the Offer to Purchase, dated February 19, 2010, as amended and supplemented (the Offer to
Purchase), and in the related Letter of Transmittal for the Preferred Shares and the Letter of
Transmittal for the Common Shares (each, as the context requires, the Letter of Transmittal),
which, together with any amendments or supplements thereto, collectively constitute the Offer.
This Amendment is being filed on behalf of Acquisition Corp. and Haemonetics.
The information set forth in the Offer to Purchase, including Annex I thereto, the Letter of
Transmittal for the Common Shares and the Letter of Transmittal for the Preferred Shares, copies of
which are filed with the Schedule TO as Exhibits (a)(1)(A), (a)(1)(B) and (a)(1)(C) thereto,
respectively, is incorporated by reference in the answers to Items 1 through 9 and Item 11 of the
Schedule TO and this Amendment, as applicable, and is supplemented by the information specifically
provided in the Schedule TO and this Amendment.
Except as specifically provided herein, this Amendment does not modify any of the information
previously reported on the Schedule TO. You should read this Amendment together with the Schedule
TO and the information incorporated therein. Capitalized terms used and not otherwise defined in
this Amendment shall have the meanings assigned to such terms in the Offer to Purchase or in the
ITEM 4. TERMS OF THE TRANSACTION
The Offer to Purchase, incorporated by reference in its entirety into Item 4(a) of the
Schedule TO, is hereby amended as set forth in Item 11 of this Amendment.
ITEM 11. ADDITIONAL INFORMATION.
The information incorporated by reference into Item 11(a)(5) of the Schedule TO is amended by
the following amendment to the Offer to Purchase:
THE TENDER OFFER Section 17 (Legal Proceedings)
The text of the last paragraph of this section is hereby deleted in its entirety and replaced
by the following:
On March 9, 2010, the Plaintiff, Plaintiff Sham and Plaintiff OBrien (together, the
Consolidated Plaintiffs), having sought consolidation of the Action, the JFS Action and the
OBrien Action pending in the District Court Jefferson County in Golden, Colorado, jointly filed in
each of these three purported class actions an amended class action complaint against the
Defendants (the Amended Complaint). On March 10, 2010,
the court entered an order consolidating the three actions. The
consolidated action is captioned In re Global Med Technologies,
Inc. Shareholder Litigation, Case No. 2010CV673. The Amended Complaint aggregates and restates the
allegations and causes of action of the Action, the JFS Action and the OBrien Action.
Additionally, the Consolidated Plaintiffs claim that the director Defendants breached their
fiduciary duties to Global Meds stockholders by failing to make allegedly material disclosures to
the stockholders in Global Meds Schedule 14D-9 concerning additional details underlying the
fairness opinion of St. Charles Capital, LLC delivered to Global Med and certain background
information. Further, the Amended Complaint alleges that the director Defendants approved the
proposed transaction in order to provide liquidity to Global Meds largest stockholder. Based on
these allegations, the Amended Complaint seeks judgment that, among other relief: (1) provides
injunctive relief that preliminarily and permanently enjoins the Offer; (2) rescinds the Offer if
it is consummated; (3) directs the
Defendants to account to the Plaintiff and other members of the class for all damages and any
profits and other special benefits allegedly obtained by the Defendants as a result of director
Defendants alleged breaches of their fiduciary duties; and (4) awards the Consolidated Plaintiffs
the costs of the action, including fees and expenses of the Consolidated Plaintiffs attorneys and
experts. We and Haemonetics believe that the Amended Complaint is without merit and plan to
vigorously defend against it.
We, Haemonetics and Global Med are not aware of any material pending legal proceeding, other
than as set forth in this Offer to Purchase, relating to the Offer or the Merger.
The Offer to Purchase, incorporated by reference in its entirety into Item 11(b) of the
Schedule TO, is hereby amended as set forth in this Item 11 of this Amendment.